Incretin Atlas › Trials › ATTAIN-OSA trial 1 / trial 2
ATTAIN-OSA trial 1 / trial 2
Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D)
Design
- Molecule(s)
- Orforglipron
- Population
- Obstructive sleep apnoea + obesity or overweight (no T2D)
- Official title
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2024-10 → 2026-07
- Participants
- 712
- Duration
- 52 weeks
- Registry
- NCT06649045
Outcomes in the indication
ATTAIN-OSA trial 1 / trial 2 Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D) · 52 weeks · n = 712 abstract
AHI −13.2 (trial 1, no PAP) and −12.0 (trial 2, on PAP) events/h vs placebo at 52 weeks, treatment-regimen estimand; 6 of 7 key secondary end points significant.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 1, no PAP week 52 | −17.8 | −4.5 | −13.2 (−17.7 to −8.7) events/h | abstract |
| Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 2, on PAP week 52 | −17.3 | −5.3 | −12.0 (−17.1 to −6.9) events/h | abstract |
Verbatim quotes (2)
- Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001)
- Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
In trial 2, the mean AHI change was -17.3 for orforglipron and -5.3 for placebo (difference, -12.0 [95% CI, -17.1 to -6.9]; P < .001)
Primary sources
- Malhotra A, Gottlieb DJ, Woehrle H, Dennehy EB, Calamai G, Liu Z, et al. Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. 2026. PMID: 43002161.
- Eli Lilly and Company. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (ATTAIN-OSA). ClinicalTrials.gov identifier NCT06649045. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06649045
How to cite this page
Medical Adviser's Group. Incretin Atlas: ATTAIN-OSA trial 1 / trial 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-osa-trial-1-trial-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.